← Leaderboards
David H Peyton
Designmedix, Inc.
$6,212,451
Attributed
$6,389,402
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2007–16$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$6,389,402 · 7
By mechanism
R42$4,310,664 · 2
R41$1,057,778 · 3
R56$624,455 · 1
R21$396,505 · 1
Top collaborators
- Lars Eckmann1 shared
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceDesignIn VivoDrug ResistancePharmaceutical PreparationsParasitesChloroquine ResistanceStructure-Activity RelationshipVacuoleMalariaAntimalarialsIn VitroChloroquineDoseChildKillingsPlasmodium FalciparumCombined Modality TherapyEvaluationLeadPregnant WomenCytotoxicityCarrier ProteinsMulti-Drug Resistance
Grant awards (12)
Preclinical development of novel small molecule malaria drugs that overcome drug$994,275
R42 · FY2016 · AI · contact PI
High-potency nitro antimicrobials for topical treatment of trichomoniasis$353,902
R41 · FY2016 · AI · contact PI
Preclinical development of novel small molecule malaria drugs that overcome drug$999,700
R42 · FY2015 · AI · contact PI
Preclinical development of novel small molecule malaria drugs that overcome drug$989,081
R42 · FY2014 · AI · contact PI
Preclinical development of novel small molecule malaria drugs that overcome drug$300,000
R41 · FY2012 · AI · contact PI
Preclinical development of novel small molecule malaria drugs that overcome drug$300,000
R41 · FY2011 · AI · contact PI
Designed Antimalarial Agents Overcoming Chloroquine-Resistance$644,773
R42 · FY2010 · AI · contact PI
Pre-clinical Safety and Efficacy of Reversed Chloroquines$624,455
R56 · FY2010 · AI · contact PI
Designed Antimalarial Agents Overcoming Chloroquine-Resistance$682,835
R42 · FY2009 · AI · contact PI
Reversed Chloroquines as Antimalarial Agents$214,839
R21 · FY2008 · AI · contact PI
Reversed Chloroquines as Antimalarial Agents$181,666
R21 · FY2007 · AI · contact PI
Designed Antimalarial Agents Overcoming Chloroquine-Resistance$103,876
R41 · FY2007 · AI · contact PI